PDCD1 and nasopharyngeal carcinoma: Given the rapid advancements in immunotherapy, Programmed cell death 1 (PD‐1)/Programmed cell death ligand 1 (PD‐L1) inhibitors have emerged as the established first‐line therapeutic option for RM‐NPC.7, 8, 9